secwatch.observer — SEC 8-K summary
======================================

Issuer:     Phio Pharmaceuticals Corp. (PHIO)
CIK:        0001533040
Form:       8-K
Filed at:   2025-11-13T23:59:59+00:00
Accession:  0001437749-25-034848
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Phio Pharma Q3 net loss $2.4M; PH-762 trial 100% tumor clearance at max dose
----------------------------------------------------------------------------

- Net loss $2.4M for Q3 2025 vs $1.5M in Q3 2024; R&D expenses $1.2M, G&A $1.3M.
- Phase 1b PH-762 trial: 100% tumor clearance (complete response) in one patient at max dose, >90% in second, >50% in third.
- Cumulative pathologic results in 16 cSCC patients: 6 complete, 2 near complete, 2 partial responses; no dose-limiting toxicities.
- November 2025 warrant inducement financing expected to raise ~$12.1M, extending cash runway into first half 2027.
- Cash and equivalents $10.7M at Sep 30, 2025; estimated $21.3M as of release date.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1533040/000143774925034848/0001437749-25-034848-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1533040/000143774925034848/phio20251001_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-034848

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer